Exelixis, Inc. (EXEL)
EXEL moved a median of -0.02% 30 minutes after news, and +0.04% by the close. How EXEL actually reacts to news — the realized, point-in-time move the market made, measured across 548 labeled events over the last three years with zero look-ahead.
EXEL’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.03% | 51% | 546 |
| 30-min | -0.02% | 49% | 546 |
| 60-min | -0.03% | 44% | 546 |
| to close | +0.04% | 52% | 537 |
| Middle 50% of EXEL reactions | -0.50% to +0.69% |
|---|---|
| Median reaction (30-min) | -0.02% |
| Measured reactions | 548 |
Half of all Exelixis, Inc. news events land between -0.50% and +0.69% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How EXEL reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 29 | +0.17% | 52% | +0.47% |
| Analyst downgrades | 43 | -0.17% | 37% | -0.96% |
| Coverage initiations | 29 | +0.50% | 69% | +0.26% |
| Rating reiterations | 170 | +0.10% | 54% | +0.09% |
| Price-target raises | 59 | +0.08% | 58% | +0.20% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 1 further class was observed with fewer than 10 measured events and is not published. See how EXEL ranks against every other measured name →
That’s how EXEL usually reacts — get an email when it moves on news →Email me when EXEL moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to EXEL's baseline. Nothing else.
Recent EXEL events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda | Press release | Canada Newswire | -0.28% | +1.79% | |
| Form 8-K EXELIXIS, INC. For: Sep 10 | SEC filing · Form 8-K | SEC EDGAR | -1.98% | -0.76% | |
| Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September | Press release | Business Wire | +2.47% | +2.31% | |
| Exelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories | Press release | Business Wire | -0.03% | +0.62% | |
| Form 8-K EXELIXIS, INC. For: Aug 31 | SEC filing · Form 8-K | SEC EDGAR | +0.88% | +3.91% | |
| EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with SBS Law | Press release | Business Wire | +0.37% | +2.09% | |
| Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update | Press release | Business Wire | +1.10% | -1.36% | |
| Form 10-Q EXELIXIS, INC. For: Jul 03 | SEC filing · Form 10-Q | SEC EDGAR | +1.10% | -1.36% | |
| Form 8-K EXELIXIS, INC. For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | +1.10% | -1.36% | |
| Form S-8 EXELIXIS, INC. | SEC filing · Form S-8 | SEC EDGAR | +1.10% | -1.36% | |
| Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026 | Press release | Business Wire | +0.17% | +1.77% | |
| Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer | Press release | Business Wire | +0.63% | -1.25% | |
| Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026 | Press release | Business Wire | +0.08% | -0.53% | |
| Form 8-K EXELIXIS, INC. For: May 26 | SEC filing · Form 8-K | SEC EDGAR | +0.08% | -0.53% | |
| Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June | Press release | Business Wire | +0.63% | +2.82% | |
| Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types | Press release | Business Wire | +0.73% | +0.80% | |
| Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer | Press release | Business Wire | -1.81% | -1.62% | |
| Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May | Press release | Business Wire | +0.83% | +3.37% | |
| Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update | Press release | Business Wire | -0.18% | +2.70% | |
| Form 10-Q EXELIXIS, INC. For: Apr 03 | SEC filing · Form 10-Q | SEC EDGAR | -0.18% | +2.70% | |
| Form 8-K EXELIXIS, INC. For: May 05 | SEC filing · Form 8-K | SEC EDGAR | -0.18% | +2.70% | |
| Exelixis to Release First Quarter 2026 Financial Results on Tuesday, May 5, 2026 | Press release | Business Wire | -0.79% | +1.12% | |
| Form DEFA14A EXELIXIS, INC. | SEC filing · Form DEFA14A | SEC EDGAR | -0.11% | -3.07% | |
| Form DEF 14A EXELIXIS, INC. For: May 26 | SEC filing · Form DEF | SEC EDGAR | +0.34% | +0.57% | |
| Form DEFA14A EXELIXIS, INC. | SEC filing · Form DEFA14A | SEC EDGAR | +0.34% | +0.57% | |
| Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March | Press release | Business Wire | +0.46% | -1.43% | |
| Oncology Market Set to Nearly Triple: Here Are Five Companies Leading the Charge | Press release | PR Newswire | +0.39% | +2.75% | |
| Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update | Press release | Business Wire | -2.53% | -1.20% | |
| Form 10-K EXELIXIS, INC. For: Jan 02 | SEC filing · Form 10-K | SEC EDGAR | -2.53% | -1.20% | |
| Form 8-K EXELIXIS, INC. For: Feb 10 | SEC filing · Form 8-K | SEC EDGAR | -2.53% | -1.20% | |
| Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer | Press release | Business Wire | -2.69% | +1.90% | |
| Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026 | Press release | Business Wire | -0.01% | -1.98% | |
| Form 8-K EXELIXIS, INC. For: Jan 11 | SEC filing · Form 8-K | SEC EDGAR | +0.47% | +0.04% | |
| Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026 | Press release | Business Wire | -0.88% | +3.16% | |
| Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer | Press release | Business Wire | +0.72% | +4.38% | |
| Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026 | Press release | Business Wire | +0.72% | +4.38% | |
| Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025 | Press release | Business Wire | +0.70% | +0.91% | |
| Form 8-K EXELIXIS, INC. For: Nov 04 | SEC filing · Form 8-K | SEC EDGAR | +0.17% | +0.93% | |
| Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November | Press release | Business Wire | -0.65% | +0.44% | |
| Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update | Press release | Business Wire | +2.63% | +0.93% | |
| Form 10-Q EXELIXIS, INC. For: Oct 03 | SEC filing · Form 10-Q | SEC EDGAR | +2.63% | +0.93% | |
| Form 8-K EXELIXIS, INC. For: Nov 04 | SEC filing · Form 8-K | SEC EDGAR | +2.63% | +0.93% | |
| Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 | Press release | Business Wire | +0.28% | +0.17% | |
| SynOx Therapeutics Strengthens Board of Directors with Leading Experts in Commercialisation and Corporate Development Amid Continued Corporate Progress | Press release | GlobeNewswire | +0.41% | +3.08% | |
| Exelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO 2025 and Published in The Lancet | Press release | Business Wire | -0.66% | -2.98% | |
| Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025 | Press release | Business Wire | -0.66% | -2.98% | |
| Exelixis Announces Appointment of Dana T. Aftab, Ph.D. as Executive Vice President, Research and Development | Press release | Business Wire | +0.98% | -0.19% | |
| Form 8-K EXELIXIS, INC. For: Aug 29 | SEC filing · Form 8-K | SEC EDGAR | +0.98% | -0.19% | |
| Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September | Press release | Business Wire | -0.53% | -1.35% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Exelixis, Inc. (EXEL) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | +0.18% | -0.68% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the EXEL section they belong to.
Where else EXEL is measured.
EXEL earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Eagle Pharmaceuticals, Inc. (EGRX) | 555 | 0.00% | 44% |
| Titan Medical Inc. - Ordinary Shares (TMDI) | 552 | -0.06% | 43% |
| ACHAOGEN (AKAO) | 547 | -0.26% | 44% |
| FIBROCELL SCIENCE INC COMMON (FCSC) | 547 | -0.17% | 43% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Exelixis, Inc.'s median reaction calculated?
Every labeled EXEL news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 548 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 49% of EXEL's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does EXEL's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.